Subcutaneous Daratumumab in Patients (PTS) With Relapsed or Refractory Multiple Myeloma (RRMM):An Open-Label, Multicenter, Dose Escalation Phase 1B Study (PAVO)

Authors :: Mateos V, M.
Chari, A.
Nah, H.
Lokhorst, H.
Kaufman, J. L.
Moreau, P.
Oriol, A.
Plesner, T.
Benboubker, L.
Hellemans, P.
Masterson, T.
Clemens, P. L.
Liu, K.
San-Miguel, J.
Usmani, S. Z.
Source :: Mateos V, M, Chari, A, Nah, H, Lokhorst, H, Kaufman, J L, Moreau, P, Oriol, A, Plesner, T, Benboubker, L, Hellemans, P, Masterson, T, Clemens, P L, Liu, K, San-Miguel, J & Usmani, S Z 2018, ' Subcutaneous Daratumumab in Patients (PTS) With Relapsed or Refractory Multiple Myeloma (RRMM) : An Open-Label, Multicenter, Dose Escalation Phase 1B Study (PAVO) ', Haematologica, vol. 103, no. Suppl. 1, pp. 32-33 .
Publication Year :: 2018

Language :: English
Database :: OpenAIRE
Journal :: Mateos V, M, Chari, A, Nah, H, Lokhorst, H, Kaufman, J L, Moreau, P, Oriol, A, Plesner, T, Benboubker, L, Hellemans, P, Masterson, T, Clemens, P L, Liu, K, San-Miguel, J & Usmani, S Z 2018, ' Subcutaneous Daratumumab in Patients (PTS) With Relapsed or Refractory Multiple Myeloma (RRMM) : An Open-Label, Multicenter, Dose Escalation Phase 1B Study (PAVO) ', Haematologica, vol. 103, no. Suppl. 1, pp. 32-33 .
Accession number :: edsair.od......3062..af2e2756418b66aa6f509fe24b5e524d

Tools